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ABSTRACT A feature of the expression of the tissue-
specific class I antigen Qa-2 is the quantitative variation
among mouse strains. Recently, the class I gene Q7 has been
shown to encode a protein product that is biochemically
indistinguishable from the lymphocyte-bound Qa-2 molecule.
Utilizing gene transfection, we have identified a second Qa-2
subregion class I gene (Q9), in H-2b mice, which encodes a
polypeptide biochemically similar to the Q7 and the Qa-2
polypeptides. Furthermore, we have observed that cell lines
transfected with the allelic forms of the Q7 gene from
C57BL/10 (Qa-2hi) or BALB/C (Qa-2Iow) display quantita-
tive differences in cell-surface expression. Based on these
studies, we suggest that gene dosage and allele-specific varia-
tion in cell-surface expression contribute to the strain-specific
variation in the levels of Qa-2 antigen expression.
and the cell surface molecule is attached to the cell surface
by a lipase-sensitive membrane anchor. These two proper-
ties are characteristic of the lymphocyte Qa-2 molecule (13,
14).
Two allelic forms of the Qa-2 locus have been defined
based on the ability of lymphocytes from mouse strains to
express (Qa-2+ or Qa-2a) or not express (Qa-2 - or Qa-2b)
serologically defined Qa-2 antigens. Furthermore, among
mice that express Qa-2 antigens, there is quantitative varia-
tion in the levels of expression ofQa-2 (5, 6, 15-17). Utilizing
gene transfection to analyze Qa region class I gene expres-
sion, we have obtained evidence indicating that gene dosage
and transcriptional/posttranslational processing both con-
tribute to the strain-specific variation in lymphocyte Qa-2
expression.
The murine major histocompatibility complex-encoded
H-2K, H-2D, and H-2L class I molecules are highly poly-
morphic, ubiquitously expressed cell-surface glycoproteins
that serve fundamental roles in the rapid rejection of
tissue/organ grafts and in antigen recognition by T cells (1).
Serological, biochemical, and molecular approaches have
determined that the chromosomal segment located telomeric
to the murine H-2 major histocompatibility complex encodes
at least three cell surface (Qa-1, Qa-2, and TL) and two
soluble/secreted (Q10 and Qb-1) polypeptides, which are
structurally related to H-2K, -D, and -L (2-4). Unlike their
counterparts H2-K, -D, and -L, the Qa/TL polypeptides
exhibit low polymorphism and are expressed in a tissue-
specific fashion (5, 6). The function(s) of the Qa/TL mole-
cules is unknown.
Twenty to thirty distinct class I genes have been localized
to the Qa/TL chromosome segment of BALB/c and
C57BL/10J (B10) mice (7, 8). Gene transfection studies have
been utilized to identify those Qa/TL region genes that
encode the biochemically and serologically defined Qa/TL
proteins. Analysis of mouse L cell fibroblasts transfected
with the Q6b, Q7b, Q8b, or Q9b genes led to the identification
of intracellular polypeptides that are reactive with Qa-2
antiserum (9). Recently the Q7b gene transfected into a
mouse T-cell line and the Q7b and Q7d genes transfected into
a mouse liver cell line have been shown to encode cell-
surface proteins reacting with several serological reagents
that detect Qa-2-specific molecules on lymphocyte cell sur-
faces (10, 11). Biochemical studies have determined that the
Q7 gene derived from either BALB/c (Q7d) or B10 (Q7b)
mice encodes a Mr 40,000 cell-surface polypeptide that is
biochemically and serologically indistinguishable from the
Qa-2 polypeptide expressed on lymphoid cell surfaces (12).
It has been demonstrated that the Q7d and Q7" genes encode
both a membrane bound and a secreted soluble polypeptide,
MATERIALS AND METHODS
Serological Reagents. Anti-Qa-2 antiserum was produced
by the immunization protocol of Flaherty (5). The monoclo-
nal antibodies (mAbs) 20-8-4 (anti-K", -Kb, -r, -s, -Qa-2),
34-1-2 (anti-K , -D , -L , -Kb -r, -s, -p, -q, -Qa-2), 28-14-8
(anti-Ld', -Db), 11-4-1 (anti-Kk), and anti-Qam8 were purified
on protein A-Sepharose as described (12). The mAb Qam2
was purchased from Accurate Scientific Company (Hicks-
ville, NY). Normal mouse serum was purchased from Pel-
Freeze. The Qam7 and D3262 mAbs were partially purified
from ascitic fluid and coupled to CNBR-activated Sepharose
4B as described in detail (12). Protein A-Sepharose was
purchased from Genzyme (Boston, MA).
Establishment of Transfected Cell Lines. Thymidine ki-
nase-negative (TK-) L cells (C3H fibroblastic, H-2k) desig-
nated as L cells, hepatoma cells (Hepa-1), and primary liver
cells (CRL-3A) were used in our previous studies (12).
Plasmid 27.1 was described earlier (12). Plasmid clones
containing the EcoRI fragments carrying the B10 Q7b, Q8b,
and Q9b genes were provided by David Sherman, Gerry
Waneck, and Richard Flavell (Biogen Research, Cambridge,
MA) (18). Transfections were carried out by the calcium
phosphate coprecipitation method (19) as described (12)
using -1 ,g of plasmid DNA encoding the class I gene, 15 ng
of pSV2-neo plasmid (20), and 10 ug of carrier L TK- DNA
per 5 x 106 cells. Both mixed populations of transfectants
and cloned cell lines were analyzed. Individual clones were
isolated by plating cells at limiting dilution. Under conditions
used in our studies, >90% of the clones in the mixed
populations of transfectants selected for G418 resistance
were also cotransfected with the class I gene. Levels of
Q-region class I gene expression were determined by a
sensitive cell binding radioimmunoassay using the mAb
20-8-4 as described (21).
Abbreviations: B6, C57BL/6J mice; B1O, C57BL/1OJ mice; mAb,
monoclonal antibody; TK, thymidine kinase; Endo-F, endoglycosi-
dase F; PtdIns, phosphatidylinositol.
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Radiolabeling and Immunoprecipitation. Con A-activated
lymphoid cells from C57BL/6J (B6) mice were prepared as
described (12, 14). L cells, Hepa-1 cells, and lymphoid cells
were harvested, washed with phosphate-buffered saline, and
radiolabeled either by lactoperoxidase-catalyzed iodination
or metabolically with [35S]methionine (14). The preparation
of Nonidet P-40 cell lysates and cell-free medium from
radiolabeled cells has been described in detail (12, 14). Cell
lysates and cell-free medium were precleared and treated
with the appropriate serological reagents or mAb coupled to
Sepharose. Immune complexes were absorbed to protein
A-Sepharose, washed, and analyzed by one- or two-dimen-
sional polyacrylamide gel analysis (14). In some cases, the
Q7b and Q9b polypeptides were enzymatically deglycosyla-
ted by using endoglycosidase F (Endo-F, New England
Nuclear) prior to two-dimensional analysis (22).
Phospholipase C Treatment of Cells. Hepa-1 cells transfec-
ted with the Q7b or Q9b genes were radiolabeled by lacto-
peroxidase-catalyzed iodination, washed, and resuspended
at 107 cells per ml in RPMI 1640 medium containing 2 mg of
bovine serum albumin (fraction IV, Sigma) per ml, gluta-
mine, vitamins, and nonessential amino acids. Purified phos-
phatidylinositol (PtdIns)-specific phospholipase C from Bac-
cillus thermongenious was incubated with cells for 2 hr at
37°C (23). After incubation, the cells and cell-free medium
were recovered by centrifugation, and the distribution of Q7
or Q9 molecules in cell lysates or cell-free medium was
determined by immunoprecipitation and PAGE.
RESULTS
Establishment of Q9b Gene Transfectants. Previous studies
have established that the Qa subregion of the B10 (H-2b)
mouse encodes 10 class I genes (designated QJ-QJO), while
the BALB/c (H-2d) mouse contains only 8 Qa genes (8, 24).
A comparison of the class I Qa sequences revealed that the
BALB/c strain lacks the Q3 gene and carries a hybrid Q8/9
gene. It is likely that this hybrid gene has been created by a
fusion of ancestral BALB/c genes equivalent to B10 Q8b andQ9b genes (8, 24). DNA restriction mapping and hybridiza-
tion studies have shown that, within the Q4 to QJO group of
genes, alternating genes are more similar to each other than
to the adjacent genes (8). This homology is strongest be-
tween the Q6-Q7 gene pair and Q8-Q9 gene pair. Accord-
ingly, the BALB/c strain contains a single Q6d-Q7d gene
pair, while the B10 strain contains two pairs: 6b-Q7b andQ8b-Q9&. We have shown previously that Q7 is the only
BALB/c Qa region gene that can be expressed in transfected
cells as a cell-surface product biochemically similar to clas-
sically defined Qa-2 antigen. We have also demonstrated
that its allelic equivalent from the B10 strain, Q7b, has
identical serological and biochemical properties.
To assess coding properties of the Q8b.Qpb gene pair and
their potential contribution to the Qa-2 phenotype in the B10
mouse, we have established cell lines transfected with Q8b
and Q9b genes. Cloned Q8b and Q9b genes (18) were intro-
duced stably into hepatoma cells by the calcium phosphate
precipitation method using pSV-2neo plasmid as a selectable
marker. The recipient cells, Hepa-1, were shown previously
to be permissive for cell-surface expression of Qa-2 antigen
(12). Expression of Q gene products was monitored with
mAbs 20-8-4 and 34-1-2, which are diagnostic for Qa proteins
(12, 15). Q9b gene transfectants reacted with these reagents
when tested by a highly sensitive cell-binding radio-
immunoassay. Q8b-transfected Hepa-1 cells tested negative
in this assay. Screening of mixed populations of Hepa-1
transfectants was confirmed by three independent transfec-
tion experiments (data not shown). The results of these
experiments indicate that Q9b, but not Q8b, encodes in
Hepa-1 cells a cell-surface Qa-2-like product. This is con-
sistent with DNA homology studies (18) that suggested that
Q9 gene is very similar to the Q7 gene, while Q8 gene is
similar to the Q6 gene.
To test if Q9" gene expression is liver specific, we have
transfected a rat-derived primary cloned liver cell line,
CRL-3A, and, as a control, the fibroblastic L cell line. As
observed for Q7 genes (12), Q9" expression was detectable
on the cell surface of CRL-3A cells but not on L cells.
Biochemical Characterization of the Q9b Protein Product.
We have reported that Q7b gene expression is sufficient to
explain serological and biochemical heterogeneity of Qa-2
antigen(s) on the B6 spleen (12). Since transfection experi-
ments identified the Q9b gene as potentially contributing to
Qa-2 phenotype, we have performed a series of experiments
to compare Q7b, Q9b, and B6 spleen Qa-2 properties. Hepa-1
cells transfected with either the Q7b or the Q9b gene as well
as activated T-cell populations from B6 mice were radiola-
beled by lactoperoxidase-catalyzed iodination. Cell-surface
molecules immunoprecipitated by anti-Qa-2 sera (B6.K1
anti-B6) were analyzed by two-dimensional gel electropho-
resis (Fig. 1). The anti Qa-2 sera recognized a Mr 40,000
polypeptide on the surface of Q9b-transfected Hepa-1 cells
that is indistinguishable by charge or molecular weight from
the Q7b polypeptide or the Qa-2 polypeptide expressed on
lymphoid cells. This is consistent with our initial observation
and suggests that B6 Qa-2 antigens are composed of two
superimposed patterns of Q7b and Q9b products. Treatment
of the Mr 40,000 Q7b or Q9b polypeptide with the enzyme
Endo-F reduced the Mr to -34,000. This reduction in
molecular weight is consistent with the removal of two
N-linked carbohydrate chains as predicted from Q7b and Q9b
DNA sequences (18, 22). Interestingly, the deglycosylated
Q7b and Q9b core polypeptides displayed reproducibly dis-
tinct isoelectric patterns (compare B and D in Fig. 1). Both
Q7b and Q9b contain three isoelectric species of which two
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FIG. 1. Biochemical analysis of the Q7b and Q9b polypeptide.
Cell lysates from I'25-radiolabeled Hepa-1 cells transfected with
either Q7b or Q9" and B6 activated T cells were immunoprecipitated
with anti-Qa-2 serum. Isolated molecules were treated with (Right)
and without (Left) Endo-F and analyzed by two-dimensional gel
analysis. Displayed is analysis of the fully glycosylated (A, C, E, and
G) or Endo-F-deglycosylated (B, D, F, and H) Q7b polypeptide (A
and B), Q9b polypeptide (C and D), a mixture of Q7b and Q9b (E and
F), and lymphoid Qa-2 polypeptides (G and H). Only relevant
regions of the autoradiogram are displayed. Positions of known
molecular weight markers (shown x 1o-3) run in parallel are
indicated.
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major spots are common. In addition, Q9b has a unique
acidic species, whereas Q7b has a unique basic species.
When a mixture of the deglycosylated Q7b and Q9b species
were analyzed, a series of four spots was observed (Fig. 1F).
The middle two common spots displayed an increase in
intensity, and the unique acidic (Q9b) and basic (Q7b) species
remained less intense. Importantly, the isoelectric pattern
observed in a mixing experiment was identical to the degly-
cosylated Qa-2 molecules identified in activated lymphoid
cell populations of the B6 mice. Based on these observa-
tions, we propose that the Qa-2 molecules expressed by the
Qa-2hi strain B10 (and B6) are encoded by at least two
Q-region class I genes: Q7b and Q9b.
Serological Comparison of the Q7 and the Q9 Polypeptides.
Previous studies have shown that the Q7 polypeptide is
recognized by a battery of serological reagents that detect
Qa-2 subregion-controlled serological determinants (12). We
wished to determine whether these reagents likewise de-
tected the Q9b-encoded polypeptide. Hepa-1 cells, express-
ing either the Q7b or Q9d polypeptides, were immunoprecip-
itated with various serological reagents and analyzed by
one-dimensional PAGE (Fig. 2). Anti-Qa-2 serum as well as
the mAbs 20-8-4, 34-1-2, Qam2, Qam7, Qam8, and D3262
recognized a Mr 40,000 polypeptide expressed on the surface
of Q7b- or Q9b-transfected cells (Fig. 2, lanes A-H). Thus,
based on the reagents utilized in this study, the Q9b, Q7b,
and Q7d cell-surface products are serologically indistinguish-
able.
The Q7b and Q9b Genes Encode Lipase-Sensitive Cell-
Surface and Secreted Soluble Polypeptides. The Q7 polypep-
tides expressed on Hepa-1 cells as well as the Qa-2 mole-
cules expressed on lymphoid cells have been shown to be
attached to the cell membrane via a PtdIns-bearing mem-
brane anchor sensitive to cleavage with a phospholipase C
(12, 13). We sought to determine whether the Q9 polypeptide
was likewise attached to the cell surface by a lipase-sensitive
anchor structure. Hepa-1 cells transfected with either Q7b or
Q9b were radiolabeled by lactoperoxidase catalyzed-iodin-
ation and incubated in the presence of various concentra-
tions of a Ptdlns-specific phospholipase C purified from
Baccillus thuringiensis (23). After incubation, both cell ly-
sates and cell-free media were immunoprecipitated with the
anti-Qa-2 reagents and analyzed by NaDodSO4/PAGE (Fig.
3). Results showed that both the Q7b and Q9b molecules
display identical sensitivity to the PtdIns-specific phospho-
lipase C purified from B. thuringiensis.
The Q7 and Qa-2 polypeptides are synthesized as both
cell-surface and soluble secreted forms (12, 14, 25). To
explore whether the Q9b polypeptide was likewise synthe-
sized in the secreted soluble form, Hepa-1 cells transfected
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FIG. 3. Lipase sensitivity of Q7b and Q9b. 125I-radiolabeled
Hepa-1 cells transfected with Q7b or Q9b were treated with B.
thuringiensis Ptdlns phospholipase C. After treatment, both cells
and cell-free medium were harvested, and the distribution of Q7b or
Q9b in cell lysates and cell-free medium was determined by immu-
noprecipitation and NaDodSO4/PAGE. Displayed are the Q7b
(Upper) and Q9b (Lower) recovered from the cell lysate (lanes A-C)
or cell-free medium (lanes D-F) after treatment with Ptdlns phos-
pholipase C at 0 ,g/ml (lanes A and D), 20 ,ug/ml (lanes B and E),
and 5 ,ug/ml (lanes C and F). The positions of known molecular
weight markers (shown x 10-) are indicated on the right.
with either Q7b or Q9b genes were radiolabeled with [35S]-
methionine for 4 hr. Cell-free medium was immunoprecipi-
tated with anti-Qa-2 serum and analyzed by two-dimensional
PAGE (see Fig. 4). Both Q7b- and Q9b-transfected Hepa-1
cells synthesized and secreted a Mr -39,000 soluble poly-
peptide in addition to the cell-bound products. We have
documented (12) that the Q7 gene product in transfected L
cells is exclusively expressed as a secreted soluble molecule.
Similar to Q7b and Q7d, the Q9" gene, when transfected into
L cells, synthesized a soluble secreted Mr 39,000 polypep-
tide (Fig. 4). Analogous to what was observed with the Q7b
and Q9b cell-surface proteins, the secreted soluble Q7b or
Q9b polypeptides could not be distinguished by charge or
molecular weight. Hence, it is likely that Q9 soluble prod-
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FIG. 2. Serological characterization of Q9b polypeptide. Cell
lysates from Il25-labeled untransfected Hepa-1 cells or Hepa-1 cells
transfected with the Q7b or Q9b genes were treated with various
anti-Qa-2/H-2 serological reagents and analyzed by NaDod-
S04/PAGE. Displayed are immunoprecipitates from normal mouse
serum (lanes a), anti-Qa-2 serum (lanes b), 20-8-4 (lanes c), 34-1-2
(lanes d), Qam8 (lanes e), Qam2 (lanes f), Qam7 (lanes g), and D3262
(lanes h). Also displayed are immunoprecipitates from untransfected
Hepa-1 cells treated with H.11.4.1 [anti-H-2Kk (control), lane i],
20-8-4 (lane j), and 28-14-8 (anti-H-2Db, lane k).
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FIG. 4. Biosynthesis of Q7b and Q9b polypeptides in Hepa-1 and
L cells. L-cell fibroblasts or Hepa-1 cells transfected with the Q7b or
Q9b genes were radiolabeled with [355]methionine, and the cell-free
medium was treated with anti-Qa-2 reagents. Immunoprecipitates
were analyzed by two-dimensional electrophoresis. Only selected
regions of the appropriate fluorograph are shown. Displayed are the
anti-Qa-2-reactive polypeptides found in cell-free medium derived
from Hepa-1 cells transfected with Q7b (A), Hepa-1 cells transfected
with Q9b (B), L cells transfected with Q7b (C), or L cells transfected
with Q9b (D). The arrows mark specific anti-Qa-2-reactive polypep-
tides not found in the control (normal mouse serum, not shown)
immunoprecipitates. The positions of known molecular weight
markers (shown x 10-') are indicated.
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ucts contribute to the soluble Qa-2 forms secreted from
B6-activated T cells (12).
Q7b and Q7d Display Quantitative Variation in Cell-Surface
Expression. Differences in gene dosage between BALB/c
and C57BL strains do not fully explain the observed 6-fold
variation in the levels of the Qa-2 expression between these
strains (16). Therefore, we have reasoned that the existence
of the quantitative variation of the Qa-2 phenotype may be
partially caused by variation in the levels of expression of
individual Q genes encoding different allelic forms of Qa-2
polypeptides in different strains. To examine this possibility,
we have determined whether Q7 genes isolated from a Qa-2hI
(Q7b) or a Qa-2low (Q7d) strain display quantitative variation
in the levels of cell-surface expression. Hepa-1 cells were
transfected with increasing amounts of EcoRI DNA frag-
ments containing either Q7b or Q7d genes (see Fig. 5a). Both
EcoRI segments contained equivalent 5' and 3' flanking
regions. One microgram of the transfecting class I DNA was
sufficient in both cases to observe maximal levels of Qa-2
expression in the Q7d and Q7b transfectants. In all parallel
transfections, the Q7b cells expressed =3-fold higher levels
of cell-surface products than did the Q7d cells. Q9b_
transfected Hepa-1 cells expressed Qa-2 levels comparable
to Q7b transfectants (data not shown). To test these results
at the clonal level, 20 clones were derived from the Q7d- and
Q7b-plasmid-transfected cells (Fig. Sb) and Q9b-transfected
cells (not shown). With the exception of two cell lines
expressing high levels of Q7b, cell lines derived from the Q7b
transfection of Hepa-1 displayed consistently 2- to 3-fold
higher levels of cell-surface expression than did the analo-
gous Q7d transfectants. When selected subpopulations of
these clones were analyzed for levels of Q7 polypeptide
biosynthesis and secretion, similar results were obtained
(data not shown). These observations suggest that variation
in the levels of Qa-2 expression in Qa-2hI and Qa-2Iow strains
may, in part, be explained by quantitative variation in
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FIG. 5. Comparison of cell-surface expression of Q7b and Q7d
polypeptides on Hepa-1 transfectants. (a) Increasing concentrations
of homologous EcoRI DNA fragments carrying the Q7b or Q7d genes
were transfected into Hepa-1 cells, and the levels of cell-surface
expression were measured by a quantitative RIA using mAb 20-8-4
and 1251-labeled protein A. The experimental errors from duplicate
experiments were <10o of the values shown. (b) Cell-surface
expression of Q7 products was measured as above on individual
clones derived from transfection of Hepa cells with 1 jug of Q7d- or
Q7b-containing plasmids. The results were standardized relative to
the expression of the internal control H-2Db, estimated with the
H-2Db-specific mAb 28-14-8. o, Relative level of Q7d expression in
individual clones; * relative level of Q7b expression in individual
clones. The experimental errors from duplicate experiments were
<l0o of the values shown. The average relative level of expression,
estimated for 20 clones, was: for Q7d, 0.26 0.02; and for Q7b, 0.50
+ 0.05. The dashed line indicates the level of detection measured on
untransfected Hepa-1 cells.
expression of individual alleles at the transcriptional or
posttranscriptional level.
Taken together with the gene-dosage differences between
C57BL and BALB/c strains, our data can account for the
6-fold differences in the Qa-2 expression between these high
and the low strains (16).
DISCUSSION
Strains expressing the serologically defined Qa-2 antigens
have been reported to display wide variation in the levels of
Qa-2 antigen cell-surface expression (5, 6, 15-17, 26, 27).
Several factors can control expression levels of cell surface-
proteins. These include gene dosage as well as variations in
transcriptional levels, mRNA processing/transport time,
and post-translational processing steps. To address these
possibilities, we have conducted two sets of studies. First,
the protein product of another Q-region class I gene, Q9b, a
close homologue of Q7b isolated from a Qa-2hi (B10) strain,
was biochemically characterized to determine its relation-
ship to the Q7 protein and the Qa-2 protein expiessed on
lymphoid cells. In a second approach, the allelic Q-region
class I genes Q7b and Q7d were individually transfected into
a cell line capable of supporting Q7 cell-surface expression
(Hepa-1 cells), and the levels of Q7 expression were deter-
mined by a quantitative RIA.
Gene-transfection studies have shown that the Q7b and the
Q9b genes both encode a Mr 40,000 cell-surface polypeptide.
Two-dimensional gel analysis of the Mr 40,000 Q7b, Q9b, and
lymphocyte Qa-2 molecules fails to reveal reproducible
differences between these species. However, after removal
of the N-linked carbohydrate structures, a clear difference in
charge heterogeneity was observed between the M, 34,000Q7b and Q9b core polypeptides. The complete sequences of
the Q7b and Q9b gene are known (ref. 18, D. Nickerson, I.S.,
and L.H., unpublished observation). A single base change in
exon 3, leading to a glutamine in Q7b and a glutamic acid in
Q9b at position 173, is observed. This information is consist-
ent with the observed more acidic profile of the Q9b versus
the Q7b polypeptide. Importantly, the two-dimensional gel
pattern observed when a mixture of the Q7b and Q9b core
polypeptides are analyzed is identical to the core polypep-
tide pattern obtained from B6 Qa-2 molecules. These obser-
vations, together with the findings that the Q7b and Q9b
proteins display identical serological properties and lipase
sensitivities, suggest strongly that the Q7b and Q9b genes
collectively contribute to the population of glycolipid-
anchored Qa-2 molecules expressed by lymphoid cells in the
Qa-2hi strain B10 (and B6). The finding that Q7b and Q9"
both encode a soluble Mr 39,000 protein product also indi-
cates that both genes contribute to the population of secreted
Qa-2 molecules in this strain.
The Q7b and Q9b polypeptides display reproducible
charge microheterogeneity even after removal of the N-
linked carbohydrate. Since the Q7b and Q9b polypeptides are
anchored to the cell membrane by a PtdIns-bearing gly-
colipid anchor, variation in the complex glycan component
of the anchor structure may result in charge microheteroge-
neity. However, at this time the participation of other
post-translational modifications cannot be ruled out.
Serological and biochemical studies have determined that
mouse strains can display up to 15-fold variation in the levels
of Qa-2 antigen expression on lymphocytes (5, 6, 15-17, 26,
27). Clearly, gene dosage falls short of explaining this broad
range in Qa-2 expression levels. As an alternative, variations
in transcriptional levels, mRNA processing/transport time,
and post-translational processing rates between allelic forms
of Q7 (or Q9) genes may contribute to variations in cell-
surface expression. To address this possibility, equal copy
numbers of the allelic class I genes Q7b and Q7d were
Immunology: Soloski et al.
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individually transfected into Hepa-1 cells, and the levels of
Q7 expression on the transfected cells was determined. This
analysis revealed that the Q7b-transfected cells display -3-
fold more Q7 protein on the cell surface than Qid-transfected
cells. In addition, metabolic radiolabeling of Q7b- or Q7d-
transfected Hepa-1 cells has determined that the levels of
cell-associated and secreted Q7b biosynthesis are up to
3-fold higher than Q7d (data not shown). These observations
indicate that allele-specific variation in Q7 expression may
contribute to the broad range in Qa-2 expression seen among
strains. It is not clear at this time whether the observed
differences in Q7b versus Q7d cell-surface protein expression
and biosynthesis result from variations in transcriptional
activity or protein-processing steps. Similar postulates were
put forward to explain the quantitative variation in TL
antigen expression among mouse strains (28).
Based on the above observations, we propose a model in
which both gene dosage and allelic-specific variation in
expression levels contribute, in varying degrees, to the
strain-specific Qa-2 expression levels. Thus, the high levels
of expression exhibited by B6 and B10 strains are due to the
presence of two functional Qa-region class I genes (Q7hi and
Q9"i) encoding high levels of the Qa-2 molecule. Lower
levels of expression would be accounted for by the presence
of a single gene expressing Qa-2 at a high level, two genes
expressing Qa-2 at a low level, or a single gene expressing
Qa-2 at a low level. The identification of a single Qa-2-
encoding gene (Q7d) in the Qa-2Iow strain BALB/cJ supports
this model (12). Furthermore, in the strain B6.K2, which
expresses -50% of the Qa-2 antigen levels relative to B6 (16,
17) a Q9b, but not a Q7b, equivalent has been biochemically
identified on the lymphocyte cell surface (M.J.S., unpub-
lished observation). In the analysis reported above, we have
tested only two allelic counterparts of the Q7 gene. It is
likely that additional Q7 or Q9 allelic variants exist that will
display further variation in protein expression levels. In
addition, it is possible that other, yet unidentified, class I
genes may contribute to Qa-2 antigen expression in strains of
different genetic backgrounds.
Analysis of Qa-2 antigen expression revealed that the
H-2D subregion influences Qa-2 levels (15-17). Strains bear-
ing H-2Db display high levels of Qa-2 expression, while
H-2Dd strains display lower levels. This observation led to
the suggestion that sequences in the H-2D region regulate
expression levels of Qa region class I genes. We would
suggest that the association of Qa-2 levels with the H-2D
region reflects the close linkage of the Qa-region and D-region
chromosomal segments. Thus, strains bearing H-2Db would
often bear a Qa-region segment similar to the B10 (B6) strain
and contain two high-level Qa-2-expressing class I genes.
Strains bearing H-2Dd would bear a Qa-region chromosomal
segment, similar to that described for BALB/c mice, in which
a single Q-region class I gene contributes to the cell surface
Mr 40,000 Qa-2 molecules (12, 33). Interestingly, the strain
B6.K3 (Kk,Dk,Qa_2a) displays levels of lymphocyte Qa-2
expression equivalent to BlO.A(2R) (Kk,Db,Qa_2a) and B6
(Kb,D&,Qa_2a), indicating that, in this case, the high level of
expression is independent of the H-2Db region (H. Tien and
M.J.S., unpublished observation).
The observation that the Qa-2 molecule is attached to the
cell surface via a glycolipid anchor has suggested that Qa-2
may serve a role in cell signaling analogous to that suggested
for other glycolipid-linked lymphocyte cell surface mole-
cules such as Thy-1 and TAP [Ly-6] (12, 13, 29-32). How-
ever, it is puzzling that, if such a central role is served by
Qa-2 molecules, the variation in expression levels (high >
low > null) would be tolerated. One possible explanation
would be that all strains express similar levels of glycolipid-
anchored tissue-specific class I molecules. However, in
various strains, all (Qa-2hi), some (Qa-2ow), or none (Qa-2 )
are detectable by the available anti-Qa-2 serological re-
agents.
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